A Phase I/II Study of Quizartinib in Combination With Decitabine and Venetoclax for the Treatment of Patients With Acute Myeloid Leukemia (AML)
Latest Information Update: 23 Apr 2024
At a glance
- Drugs Decitabine (Primary) ; Quizartinib (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 16 Apr 2024 Planned number of patients changed from 72 to 73.
- 07 Feb 2024 Planned number of patients changed from 52 to 72.
- 07 Feb 2024 Status changed from active, no longer recruiting to recruiting.